TiumBio Co Ltd
KOSDAQ:321550
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 990
9 270
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
TiumBio Co Ltd
Net Income (Common)
TiumBio Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TiumBio Co Ltd
KOSDAQ:321550
|
Net Income (Common)
-â‚©20.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Net Income (Common)
â‚©737.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
20%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Net Income (Common)
â‚©127B
|
CAGR 3-Years
44%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Net Income (Common)
â‚©94.3B
|
CAGR 3-Years
249%
|
CAGR 5-Years
60%
|
CAGR 10-Years
77%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Net Income (Common)
-â‚©20.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Net Income (Common)
-â‚©28.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TiumBio Co Ltd
Glance View
TiumBio Co., Ltd. engages in the development and manufacture of therapeutic drugs. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2019-11-22. The firm researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.
See Also
What is TiumBio Co Ltd's Net Income (Common)?
Net Income (Common)
-20.6B
KRW
Based on the financial report for Dec 31, 2024, TiumBio Co Ltd's Net Income (Common) amounts to -20.6B KRW.
What is TiumBio Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-24%
Over the last year, the Net Income (Common) growth was -15%. The average annual Net Income (Common) growth rates for TiumBio Co Ltd have been 13% over the past three years , -24% over the past five years .